Focal Therapeutics, Inc.

Focal Therapeutics, Inc. is a specialized medical technology firm focused on providing advanced breast surgery solutions that enhance the detection, diagnosis, and treatment of breast cancer. Founded in 2007 and headquartered in Aliso Viejo, US, Focal Therapeutics, Inc. offers innovative solutions for breast cancer treatment.

In September 2018, Hologic, Inc. acquired the company for USD 125 mn. The CEO, Steve Gex, leads the company through its operational strategies. Focal Therapeutics, Inc.

specializes in innovative breast surgery solutions aimed at enhancing the detection, diagnosis, and treatment of breast cancer. Their core product offerings include the Faxitron Path+ system, which provides high-resolution imaging with 10X geometric magnification, and the Trident® HD Specimen Radiography System, known for its rapid imaging capabilities. Additionally, they offer the LOCalizer wire-free guidance system that utilizes miniature radiofrequency identification tags for non-palpable breast lesion localization, and the TruNode system, a wireless gamma probe for radio-guided surgical procedures. Hologic’s products are designed to maximize precision while minimizing patient anxiety, supporting clinicians in delivering optimal care.

Their customer base includes leading hospitals and cancer treatment centers in the United States, as well as international markets such as Australia, Canada, and various European nations. Hologic’s revenue generation is primarily driven by the sale of advanced breast health technology and surgical devices to healthcare institutions. Transactions often occur through direct sales to hospitals and clinics, where clients purchase products like the Trident® HD and the Faxitron Path+ systems for their surgical and diagnostic needs. The company may also engage in partnerships with healthcare providers to integrate their systems into existing workflows.

Hologic’s product suite, which includes flagship products, significantly influences their revenue structure, with healthcare institutions relying on these devices for both routine and specialized breast procedures. The pricing structure for these products varies based on specific needs and institutional agreements, reflecting the high-value nature of the technology provided. Focal Therapeutics, Inc. plans to leverage the recent acquisition by Hologic, Inc.

to enhance its product offerings and expand its market presence. The funding from the acquisition, completed in September 2018 for USD 125 mn, will support the development of upcoming products designed to further improve breast cancer treatment outcomes. The company also aims to explore expansion into new geographic markets, particularly targeting regions in Europe and Asia over the next few years.